{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "WEAV",
  "name": "Weave Communications, Inc.",
  "url": "https://frontierpicks.com/dossiers/WEAV/",
  "json_url": "https://frontierpicks.com/dossiers/WEAV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "Beaten-down vertical-SaaS front-office platform for healthcare SMBs, down ~36% YTD and basing off the $4.24 low, repositioning around AI-receptionist monetization (TrueLark, 2025). Still a ~17% grower with GAAP losses, so the re-rate is optionality not yet in the numbers; a reclaim of the $8.28 52-week high with AI-revenue proof is the trigger, and the ~Aug 6 Q2 print is the catalyst.",
  "invalidation_trigger": "A weekly close below $6.00 breaks the recovery base off the April $4.24 low and voids the AI-monetization re-rating setup; a Q2 print (~Aug 6) showing revenue growth decelerating under 15% with no AI-revenue disclosure is the secondary break.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-08-07",
  "invalidation_fired": true,
  "themes": [
    "ai-enterprise-software",
    "ai-datacenter-infrastructure",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Non-GAAP operating income was positive ($3.2M in Q2 2026) while GAAP stayed a loss ($4.3M); the gap is largely stock-based comp, so compare like with like.",
    "Dollar-based net revenue retention has run below 100% (92% in Q2 2026, GRR 89%) — growth depends on new-location adds, not installed-base expansion.",
    "No separate AI receptionist / TrueLark revenue line is disclosed; AI progress is reported only as interaction volumes and attach commentary.",
    "Q3 2026 results are expected in early November; there is no company-scheduled binary before then.",
    "Guidance is given on a non-GAAP operating income basis alongside revenue; the FY2026 profit guide was raised to $12-14M on the same call that cut revenue."
  ],
  "body_markdown": "\nthough# WEAV — Weave Communications, Inc.\n\n## Current Thesis\n\nThe leg an investor was buying in this name — AI-receptionist monetization reaccelerating a steady ~17% grower and re-rating a beaten-down vertical-SaaS platform for healthcare SMBs — was tested on a dated event and failed it. Q2 2026, reported 2026-08-06, put revenue at $67.5M, +15.5% YoY against $58.5M in Q2 2025, below the $67.876M consensus and a deceleration from +17.4% in Q1 2026 and +17% for FY2025. Management cut FY2026 revenue guidance to $273–275M from $275–278M (consensus $276.937M) and guided Q3 to $68.6–69.6M against $70.486M consensus, attributing the shortfall to a go-to-market re-organisation — verticalising the inbound team and installing a new SDR model — that broke lead distribution between May and July. No AI or TrueLark revenue line was disclosed. The stock closed at $5.46 on 2026-08-14, 31.8% below the $8.00 52-week high, with RSI(14) at 32.7 and a 3-month return of +3.4%. The narrative is **dead** — the narrative failed on 2026-08-06 and the recovery structure that had been building off the April $4.24 low went with it. What remains is a profitable-on-a-non-GAAP-basis, cash-generating small-cap with no scheduled catalyst until the Q3 print, which is a different proposition than the one the prior frame described.\n\n## Bull Case\n\n- **Profitability moved the right way while revenue moved the wrong way**: Q2 2026 non-GAAP operating income $3.2M, a 4.7% margin and 460bps of YoY expansion; FY2026 non-GAAP operating income guidance was *raised* to $12–14M on the same 2026-08-06 call that cut the revenue guide.\n- **Self-funding**: Q2 free cash flow $8.7M and operating cash flow $10.2M, against $47.6M cash and equivalents plus $30.8M short-term investments at quarter-end — no financing pressure at a $5.46 close.\n- **Volume growth in the AI products is real even if the dollars are not itemised**: custom AI interactions +165% YoY and Call Intelligence interactions +143% YoY (Q2 call, 2026-08-06). These are usage counts with no revenue line attached.\n- **Record gross and net location additions in Q2**, with the largest increase in specialty medical, and payments revenue growing at roughly twice the pace of total revenue (Q2 call, 2026-08-06) — the acquisition engine was still adding logos while bookings wobbled.\n- **Distribution keeps widening**: the Elation Health EHR integration announced 2026-07-17 extends reach into primary-care practices beyond the dental core.\n- **Sell-side targets, even after cuts, sit above spot**: Piper Sandler to $8 from $12 and Stifel to $9 from $11 following the print (Simply Wall St / Yahoo Finance summary, August 2026), versus the 2026-08-14 close of $5.46.\n\n## Bear Case\n\n- **The deceleration is now three data points, not one**: FY2025 +17%, Q1 2026 +17.4%, Q2 2026 +15.5%. Piper Sandler's post-print framing put FY26 top-line growth guidance at 14.8% versus 17.0% in FY25.\n- **The guidance cut is second-half weighted**: FY2026 $273–275M with Q3 at $68.6–69.6M means the damage is being carried forward, not absorbed in the printed quarter.\n- **The cause is self-inflicted and unverifiable until November**: management said the May–July lead-distribution disruption resolves and normal execution resumes within roughly two months, but the only observable confirmation is the Q3 print.\n- **The installed base contracts in dollars**: dollar-based net revenue retention 92% and gross revenue retention 89% (Q2 call, 2026-08-06). Growth depends entirely on new-location acquisition — precisely the motion the sales re-org interrupted.\n- **Still GAAP-unprofitable**: Q2 GAAP net loss $4.3M, -$0.05 per share; the $3.3M non-GAAP net income is a different number for a different purpose.\n- **The specific disclosure the prior frame required did not arrive**: no AI or TrueLark revenue was broken out in the Q2 8-K or on the call. The monetisation case has now gone two quarters without a number.\n\n## Setup & Price Structure\n\n- Reference close $5.46 on 2026-08-14; 52-week high $8.00; 31.8% below that high; 3-month return +3.4%; RSI(14) 32.7.\n- The $6 shelf that the prior frame identified as the floor of the recovery base did not hold through the 2026-08-06 print. The higher-low sequence off the April $4.24 low is broken, and there is no reclaimed structure above current price to lean on.\n- Positioning and crowding observables, stated as observables: price sits below rather than above its rising averages, so there is no extended-long condition to unwind; the 2026-08-06 and 2026-08-07 press coverage was mechanical \"IT stocks moving\" listings rather than sustained retail interest; sell-side targets of $8–$10 remain well above the $5.46 close, a spread that resolves either through further target cuts or through price; no insider transactions appear in the recent filing record reviewed for this update.\n- There is no earnings date inside the next 30 days, which removes the binary that dominated the July frame and leaves the name to drift with small-cap software risk appetite.\n- RSI(14) at 32.7 is a stretched-down reading, not a base. A base requires a series of higher lows built after the guidance cut, and none exists yet.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-15 to 2026-09-14**: no company-scheduled binary. The Q2 print (2026-08-06) has passed and the next scheduled disclosure is the Q3 report.\n- **2026-09-30**: close of fiscal Q3 — the quarter management said sales execution returns to normal (Q2 call, 2026-08-06). The outcome is not observable until the print.\n- **~2026-11-05 (est.)**: Q3 2026 results. Resolves whether the $68.6–69.6M guide holds, whether FY2026 stays at $273–275M, and whether NRR moves off 92%.\n\n## What Would Change Our Mind\n\nThe rebuild case rests on the bookings damage being one quarter deep and self-inflicted rather than demand-driven. Three things would evidence that: a Q3 print at or above the $69.6M high end with FY2026 reaffirmed at $273–275M, dollar-based net revenue retention printing above 92%, and a first disclosed AI/TrueLark revenue contribution rather than interaction counts. On price, a weekly close back above $6.00 would reclaim the shelf lost on the print and re-open the argument that August was a washout rather than a trend change. Against that, a weekly close below $5.00 extends the break toward the April $4.24 low and removes the last structure separating this from its 52-week trough; a second FY revenue guidance cut below $273M at the November print would confirm the disruption was demand, not lead routing. The narrative label moves off dead only on a fresh base plus a printed number, not on a bounce.\n\n## Correlation Notes\n\n- Trades with small-cap software risk appetite (IGV, Russell 2000 breadth) and is rate-sensitive as a GAAP-lossmaking, long-duration cash-flow story — though the 2026-08-06 gap was idiosyncratic, driven by the company's own guidance cut rather than by the group.\n- End-market exposure is healthcare SMB practice economics: dental, optometry, veterinary, med spa and now primary care. Elective dental and med-spa spend is consumer-discretionary at the margin, so practice-level transaction volumes track household spending.\n- Payments revenue growing at roughly twice total revenue (Q2 2026) attaches part of the model to practice transaction volume rather than seat count, which links the name loosely to payment-processor volume trends.\n- Competes in the AI front-office category against vertical entrants; read-across from any peer disclosing AI receptionist pricing or attach rates applies directly to the unproven monetisation leg here.",
  "first_seen": "2026-07-15",
  "last_analyzed": "2026-08-15T09:29:46+00:00",
  "last_synthesized": "2026-08-15",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}